Dopamine covalently modifies and functionally inactivates parkin

By M. LaVoie, B. Ostaszewski, Andreas Weihofen, M. Schlossmacher, D. Selkoe. Nature Medicine, 2005

687 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Neurology

View Paper: https://www.semanticscholar.org/paper/4aed8e0f86099167ce11eeae9ce2fb397e485b89

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. H. Ko
2. Valina L. Dawson
3. T. Dawson
4. M. Mouradian
5. V. Dias
6. Christian Haass
7. E. Junn

In Neurology

1. H. Ko
2. Valina L. Dawson
3. T. Dawson
4. M. Mouradian
5. V. Dias
6. A. Lutz
7. Christian Haass
8. E. Junn

Citations in the corpus

• Expanding insights of mitochondrial dysfunction in Parkinson's disease (2006, background): “Moreover, dopamine has recently been shown to covalently modify and functionally inactivate parkin E3 ligase activity by increasing parkin insolubility in vitro and in the brains of patients with P”
• A facile method of surface modification for hydrophobic polymer membranes based on the adhesive behavior of poly(DOPA) and poly(dopamine) (2009, background): “Moreover, ip-coated solid surface could be further surface-modified and unctionalized by the adduct formation between thiol- or amineontaining molecules and dopamine coating layer [5,6].”
• The Role of Oxidative Stress in Parkinson’s Disease (2013, background): “The E3 ligase activity of parkin is impaired by posttranslational modifications induced by oxidative or nitrosative stress [310, 311].”
• Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences (2012, positive): “Oxidatively modified, misfolded parkin has indeed been found in the brains of PD patients, suggesting that inactivation of parkin may also play a role in sporadic PD (Pawlyk et al , 2003; Chung et al , 2004; Yao et al , 2004; LaVoie et al , 2005; Wang et al , 2005a).”
• PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson’s Disease (2011, positive): “Moreover, oxidative, nitrosative, and dopaminergic stress, which play important pathogenic roles in PD inactivate parkin, suggesting that parkin inactivation may play a role in sporadic PD (Chung et al., 2004; LaVoie et al., 2005; Winklhofer et al., 2003).”